An 8-year retrospective review of human albumin solution use August 2015 to March 2023; Guy's and St Thomas' NHS Foundation Trust.

IF 1.4 4区医学 Q3 HEMATOLOGY Transfusion Medicine Pub Date : 2025-03-29 DOI:10.1111/tme.13138

Asma Tameez Ud Din, Patrick Harrington, Danaee Anicee, Andrew Retter, Llywelyn Cadman-Davies, Muhammad Sajid Yazdani, Paul Holmes, Vickie McDonald, Susan E Robinson

{"title":"An 8-year retrospective review of human albumin solution use August 2015 to March 2023; Guy's and St Thomas' NHS Foundation Trust.","authors":"Asma Tameez Ud Din, Patrick Harrington, Danaee Anicee, Andrew Retter, Llywelyn Cadman-Davies, Muhammad Sajid Yazdani, Paul Holmes, Vickie McDonald, Susan E Robinson","doi":"10.1111/tme.13138","DOIUrl":null,"url":null,"abstract":"Objective: The objective of this study is to critically assess the diverse indications for HAS administration over the past 8 years at a prominent tertiary care institution in the United Kingdom.Background: This is timely and relevant, given recent developments in the field. The International Collaborative Transfusion Medicine Group (ICTMG) issued updated guidance on intravenous albumin use in March 2024, reflecting a shift towards more stringent criteria for its application, which necessitates a re-evaluation of current practices.Method: We conducted a retrospective analysis of the usage of HAS from August 2015 to March 2023. Records of all patients who received HAS during this study period were extracted from the Electronic Patient Records (EPR) of Guys and St Thomas' NHS Foundation Trust London (GSTFT). Data analysis was performed using SPSS version 20.Results: A total of 4816 patients received HAS during the audit period, with 21 231 HAS infusions. The majority of infusions were for 20% HAS, with 16 772 (79% of total) infusions for 20% HAS in 4145 patients. A total of 4459 (21%) infusions were recorded for 4.5 and 5% HAS.Conclusion: Our study provides a comprehensive analysis of albumin utilisation and TPE indications over the past 8 years at our institution, establishing a crucial baseline for refining our practices.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/tme.13138","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The objective of this study is to critically assess the diverse indications for HAS administration over the past 8 years at a prominent tertiary care institution in the United Kingdom.

Background: This is timely and relevant, given recent developments in the field. The International Collaborative Transfusion Medicine Group (ICTMG) issued updated guidance on intravenous albumin use in March 2024, reflecting a shift towards more stringent criteria for its application, which necessitates a re-evaluation of current practices.

Method: We conducted a retrospective analysis of the usage of HAS from August 2015 to March 2023. Records of all patients who received HAS during this study period were extracted from the Electronic Patient Records (EPR) of Guys and St Thomas' NHS Foundation Trust London (GSTFT). Data analysis was performed using SPSS version 20.

Results: A total of 4816 patients received HAS during the audit period, with 21 231 HAS infusions. The majority of infusions were for 20% HAS, with 16 772 (79% of total) infusions for 20% HAS in 4145 patients. A total of 4459 (21%) infusions were recorded for 4.5 and 5% HAS.

Conclusion: Our study provides a comprehensive analysis of albumin utilisation and TPE indications over the past 8 years at our institution, establishing a crucial baseline for refining our practices.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

2015年8月至2023年3月人白蛋白溶液使用的8年回顾性回顾；盖伊和圣托马斯NHS基金会信托基金。

目的：本研究的目的是批判性地评估过去8年来在英国一家著名的三级医疗机构给药的各种适应症。背景：鉴于该领域的最新发展，这是及时和相关的。国际协作输血医学小组（ICTMG）于2024年3月发布了关于静脉注射白蛋白使用的最新指南，反映了其应用标准向更严格的转变，这需要对当前做法进行重新评估。方法：回顾性分析2015年8月至2023年3月期间的HAS使用情况。本研究期间所有接受HAS治疗的患者的记录均从Guys和伦敦圣托马斯NHS基金会信托基金（GSTFT）的电子病历（EPR）中提取。数据分析采用SPSS version 20。结果：审计期间共4816例患者接受了HAS治疗，输注了21 231例HAS。大多数输注是针对20%的HAS，在4145例患者中有16772例（占总数的79%）输注针对20%的HAS。4.5%和5% HAS共记录4459次（21%）注射。结论：我们的研究提供了过去8年来我院白蛋白使用和TPE适应症的综合分析，为完善我们的实践建立了重要的基线。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Transfusion Medicine 医学-血液学

CiteScore

2.70

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Transfusion Medicine publishes articles on transfusion medicine in its widest context, including blood transfusion practice (blood procurement, pharmaceutical, clinical, scientific, computing and documentary aspects), immunohaematology, immunogenetics, histocompatibility, medico-legal applications, and related molecular biology and biotechnology. In addition to original articles, which may include brief communications and case reports, the journal contains a regular educational section (based on invited reviews and state-of-the-art reports), technical section (including quality assurance and current practice guidelines), leading articles, letters to the editor, occasional historical articles and signed book reviews. Some lectures from Society meetings that are likely to be of general interest to readers of the Journal may be published at the discretion of the Editor and subject to the availability of space in the Journal.